Measuring immune proteins during stem cell transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This study looks at how certain proteins in the blood around the time of a stem cell transplant may differ based on your blood disease and the type of donor you have. It aims to help doctors understand how to better support patients during stem cell transplants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have one of these blood conditions: acute leukemia, myelofibrosis, or myelodysplastic syndrome.
- You will be having a stem cell transplant using cells from a donor that is a close or full match (haploidentical, geno-identical, or pheno-identical).
- You cannot have lymphoma or a non-cancerous blood condition.
- You must agree to take part and allow your data to be recorded in the international transplant registry.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at natural killer (NK) cells, which are part of the immune system, in the blood of people who have had a stem cell transplant for acute leukemia or myelodysplasia. It aims to understand how these cells change after transplant and potentially predict outcomes.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This study looks at using stem cells from a donor's bone marrow or blood to treat blood cancers like leukemia or lymphoma. It compares transplants from partially matched donors with fully matched donors to see how well they work.
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.